Veneta Tablet 100 mg contains Venetoclax 100 mg, a targeted oral anticancer agent used primarily for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other hematologic malignancies. Venetoclax belongs to the class of BCL-2 inhibitors, which work by promoting programmed cell death (apoptosis) in cancer cells, helping to reduce tumor burden and improve patient outcomes.

Veneta Tablet 100 mg is indicated for adult patients who may have resistant or relapsed disease, or in combination with other chemotherapeutic agents for first-line therapy. Its oral formulation allows for convenient outpatient management while delivering potent and selective anticancer activity.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Venetoclax 100 mg per tablet

Mechanism of Action

Venetoclax in Veneta Tablet 100 mg works by:

1. Selective inhibition of BCL-2 protein – BCL-2 is overexpressed in many cancer cells and prevents apoptosis. By inhibiting BCL-2, Venetoclax restores the natural cell death pathway.

2. Induction of apoptosis in cancer cells – Promotes rapid programmed cell death, reducing the number of malignant lymphocytes.

3. Tumor burden reduction – Effective in lowering malignant cell counts in blood, bone marrow, and lymph nodes.

4. Synergistic effect with other therapies – Enhances efficacy when combined with other chemotherapeutic agents or monoclonal antibodies.

5. Targeted therapy – Minimizes effects on normal cells, reducing collateral damage compared to traditional chemotherapy.

This mechanism provides a precision oncology approach for patients with hematologic malignancies resistant to conventional therapies.

Indications

Veneta Tablet 100 mg is indicated for:

• Chronic lymphocytic leukemia (CLL) – Particularly in patients with 17p deletion or relapsed/refractory disease

• Small lymphocytic lymphoma (SLL) – Used in adults who have not responded to prior therapy

• Combination therapy – With other agents such as rituximab or obinutuzumab for first-line or relapsed disease

• Targeted management of hematologic malignancies – For patients unsuitable for intensive chemotherapy

It is intended for adult patients under strict oncological supervision.

Dosage and Administration

• Starting dose: Typically 20 mg once daily, with gradual dose escalation to 400 mg daily to reduce the risk of tumor lysis syndrome (TLS)

• Administration: Swallow tablets whole with water; can be taken with or without food

• Monitoring: Frequent blood tests are required during dose escalation to monitor white blood cell counts, renal function, and electrolyte levels

• Adjustments: Dose modification may be required in patients with renal or hepatic impairment or if adverse events occur

• Duration: Continued until disease progression or unacceptable toxicity occurs

Benefits

• Selective targeting of cancer cells through BCL-2 inhibition

• Effective for relapsed, refractory, or high-risk CLL and SLL

• Reduces tumor burden in blood, bone marrow, and lymph nodes

• Can be combined with other anticancer therapies for enhanced efficacy

• Oral administration allows convenient outpatient treatment

Precautions

• Monitor for tumor lysis syndrome (TLS), particularly during initial dosing

• Avoid abrupt discontinuation, which may affect treatment efficacy

• Use caution in patients with severe renal or hepatic impairment

• Pregnancy and breastfeeding: Venetoclax is contraindicated due to potential fetal harm

• Inform the physician of all medications, as Venetoclax interacts with CYP3A inhibitors and inducers

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects:

• Nausea, diarrhea, or vomiting

• Fatigue and headache

• Low blood cell counts (neutropenia, anemia, thrombocytopenia)

Serious side effects:

• Tumor lysis syndrome (TLS)

• Severe infections due to neutropenia

• Liver enzyme elevations

• Allergic reactions in rare cases

Immediate medical attention is required for severe bleeding, infections, or sudden kidney issues.

Storage

• Store below 25°C in a cool, dry place

• Protect from light and moisture

• Keep tablets in the original packaging until use

• Keep out of reach of children

Veneta Tablet 100 mg provides a targeted, effective, and convenient oral therapy for hematologic malignancies, offering a precision approach in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, including those with high-risk or relapsed disease.